Delivering a Cancer-Free Future
TransCode Therapeutics is a clinical-stage RNA oncology company developing iron oxide nanoparticle-based therapeutics to treat metastatic cancer. Its lead candidate TTX-MC138 targets microRNA-10b, a master regulator of metastasis, with applicability across 18+ cancer types including breast, pancreatic, and ovarian cancer. The company has received multi-year NIH SBIR Fast-Track funding to support clinical evaluation.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountApr 2026
Oct 2025
Dec 2024
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
